Last reviewed · How we verify
existing formulations of 611
existing formulations of 611 is a Small molecule drug developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | existing formulations of 611 |
|---|---|
| Sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- existing formulations of 611 CI brief — competitive landscape report
- existing formulations of 611 updates RSS · CI watch RSS
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about existing formulations of 611
What is existing formulations of 611?
existing formulations of 611 is a Small molecule drug developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd..
Who makes existing formulations of 611?
existing formulations of 611 is developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (see full Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. pipeline at /company/sunshine-guojian-pharmaceutical-shanghai-co-ltd).
What development phase is existing formulations of 611 in?
existing formulations of 611 is in Phase 1.